667 related articles for article (PubMed ID: 7693298)
41. Local and remote effects of intra-caudate administration of GABA-related drugs on Met-enkephalin release in the basal ganglia.
Bourgoin S; Artaud F; Cesselin F; Glowinski J; Hamon M
Brain Res; 1985 Dec; 361(1-2):361-72. PubMed ID: 3936593
[TBL] [Abstract][Full Text] [Related]
42. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene.
O'Kusky JR; Nasir J; Cicchetti F; Parent A; Hayden MR
Brain Res; 1999 Feb; 818(2):468-79. PubMed ID: 10082833
[TBL] [Abstract][Full Text] [Related]
43. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome.
Gerlach M; Gsell W; Kornhuber J; Jellinger K; Krieger V; Pantucek F; Vock R; Riederer P
Brain Res; 1996 Nov; 741(1-2):142-52. PubMed ID: 9001716
[TBL] [Abstract][Full Text] [Related]
44. The striatum and the globus pallidus send convergent synaptic inputs onto single cells in the entopeduncular nucleus of the rat: a double anterograde labelling study combined with postembedding immunocytochemistry for GABA.
Bolam JP; Smith Y
J Comp Neurol; 1992 Jul; 321(3):456-76. PubMed ID: 1380517
[TBL] [Abstract][Full Text] [Related]
45. Pathophysiology of chorea and bradykinesia in Huntington's disease.
Berardelli A; Noth J; Thompson PD; Bollen EL; Currà A; Deuschl G; van Dijk JG; Töpper R; Schwarz M; Roos RA
Mov Disord; 1999 May; 14(3):398-403. PubMed ID: 10348461
[TBL] [Abstract][Full Text] [Related]
46. [A case of Huntington's chorea ameliorated by electrocoagulation of the globus pallidus].
BLAVIER J; BLAVIER L
Rev Med Liege; 1962 Apr; 17():218-23. PubMed ID: 13869931
[No Abstract] [Full Text] [Related]
47. Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects.
Spokes EG; Garrett NJ; Rossor MN; Iversen LL
J Neurol Sci; 1980 Dec; 48(3):303-13. PubMed ID: 6449563
[TBL] [Abstract][Full Text] [Related]
48. Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system.
Seizinger BR; Liebisch DC; Kish SJ; Arendt RM; Hornykiewicz O; Herz A
Brain Res; 1986 Jul; 378(2):405-8. PubMed ID: 2873872
[TBL] [Abstract][Full Text] [Related]
49. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
[TBL] [Abstract][Full Text] [Related]
50. Huntington's chorea: selective depletion of activity of angiotensin coverting enzyme in the corpus striatum.
Arregui A; Bennett JP; Bird ED; Yamamura HI; Iversen LL; Snyder SH
Ann Neurol; 1977 Oct; 2(4):294-8. PubMed ID: 214022
[TBL] [Abstract][Full Text] [Related]
51. Dysregulation of the Basal Ganglia Indirect Pathway in Early Symptomatic
Callahan JW; Wokosin DL; Bevan MD
J Neurosci; 2022 Mar; 42(10):2080-2102. PubMed ID: 35058372
[TBL] [Abstract][Full Text] [Related]
52. The role of the human globus pallidus in Huntington's disease.
Singh-Bains MK; Waldvogel HJ; Faull RL
Brain Pathol; 2016 Nov; 26(6):741-751. PubMed ID: 27529459
[TBL] [Abstract][Full Text] [Related]
53. Echogenicity of basal ganglia structures in different Huntington's disease phenotypes.
Saft C; Hoffmann R; Strassburger-Krogias K; Lücke T; Meves SH; Ellrichmann G; Krogias C
J Neural Transm (Vienna); 2015 Jun; 122(6):825-33. PubMed ID: 25503829
[TBL] [Abstract][Full Text] [Related]
54. Evidence of thalamic disinhibition in patients with hemichorea: semiquantitative analysis using SPECT.
Kim JS; Lee KS; Lee KH; Kim YI; Kim BS; Chung YA; Chung SK
J Neurol Neurosurg Psychiatry; 2002 Mar; 72(3):329-33. PubMed ID: 11861689
[TBL] [Abstract][Full Text] [Related]
55. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models.
Martínez-Mir MI; Pollard H; Moreau J; Traiffort E; Ruat M; Schwartz JC; Palacios JM
Synapse; 1993 Nov; 15(3):209-20. PubMed ID: 7904088
[TBL] [Abstract][Full Text] [Related]
56. GABA content and glutamic acid decarboxylase activity in brain of Huntington's chorea patients and control subjects.
Urquhart N; Perry TL; Hansen S; Kennedy J
J Neurochem; 1975 May; 24(5):1071-5. PubMed ID: 124764
[No Abstract] [Full Text] [Related]
57. Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders.
Goto S; Hirano A; Rojas-Corona RR
Acta Neuropathol; 1989; 78(5):543-50. PubMed ID: 2479214
[TBL] [Abstract][Full Text] [Related]
58. Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease.
Ellison DW; Beal MF; Mazurek MF; Malloy JR; Bird ED; Martin JB
Brain; 1987 Dec; 110 ( Pt 6)():1657-73. PubMed ID: 2892568
[TBL] [Abstract][Full Text] [Related]
59. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study.
Augood SJ; Faull RL; Love DR; Emson PC
Neuroscience; 1996 Jun; 72(4):1023-36. PubMed ID: 8735227
[TBL] [Abstract][Full Text] [Related]
60. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease.
De Souza EB; Whitehouse PJ; Folstein SE; Price DL; Vale WW
Brain Res; 1987 Dec; 437(2):355-9. PubMed ID: 2893655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
